US 2014/0271544 A1 · COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE SUB-POPULATION

Abstract

The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in patients having genetic variations located near the IL28B gene, including SNP rs12979860 with a non-CC genotype and SNP rs8099917 with a non-TT genotype.

Claims30

Dependent claims

A method of treating hepatitis C viral (HCV) infection or alleviating one or more symptoms thereof in a patient comprising the step of administering to the patient a therapeutic combination comprising:

(a) a compound of the following formula (1) or a pharmaceutically acceptable salt thereof:
wherein B is
L1 is MeO—;
L1 is Br;
and R2 is
(b) interferon alpha;
and
(c) ribavirin;
and wherein the patient has a non-CC genotype of SNP rs12979860 or a non-TT genotype of SNP rs 8099917 located near the IL-28B gene.

6 more elements

Dependencies are inferred from the claim text.

Combination therapy for treating hcv infection in specific patient subgenotype sub-population

Life of this patent

Combination therapy for treating hcv infection in specific patient subgenotype sub-population

Life of this patent

Abstract

Claims30